BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37580822)

  • 21. Universal test and treat is not associated with sub-optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial.
    Iwuji C; McGrath N; Calmy A; Dabis F; Pillay D; Newell ML; Baisley K; Porter K
    J Int AIDS Soc; 2018 Jun; 21(6):e25112. PubMed ID: 29890048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the test and treat policy on delays in antiretroviral therapy initiation among adult HIV positive patients from six clinics in Johannesburg, South Africa: results from a prospective cohort study.
    Onoya D; Sineke T; Hendrickson C; Mokhele I; Maskew M; Long LC; Fox M
    BMJ Open; 2020 Mar; 10(3):e030228. PubMed ID: 32213514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of delayed Anti-Retroviral Therapy initiation among adults referred for HIV treatment in Uganda: a cross-sectional study.
    Kiyingi M; Nankabirwa JI; Sekaggya-Wiltshire C; Nangendo J; Kiweewa JM; Katahoire AR; Semitala FC
    BMC Health Serv Res; 2023 Jan; 23(1):40. PubMed ID: 36647104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal analysis of immune reconstitution and metabolic changes in women living with HIV: A real-world observational study.
    Wang X; Xiao J; Zhang L; Liu Y; Chen N; Deng M; Song C; Liu T; Zhang Y; Zhao H
    Chin Med J (Engl); 2023 Sep; 136(18):2168-2177. PubMed ID: 37580056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the "universal test and treat" policy on the characteristics of persons registering for HIV care and initiating antiretroviral therapy in Uganda.
    Mugenyi L; Hansen CH; Mayaud P; Seeley J; Newton R; Nanfuka M; Abaasa A; Mugisha K; Etukoit M; Kaleebu P; Ruzagira E
    Front Public Health; 2023; 11():1187274. PubMed ID: 37361157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa.
    Boyer S; Iwuji C; Gosset A; Protopopescu C; Okesola N; Plazy M; Spire B; Orne-Gliemann J; McGrath N; Pillay D; Dabis F; Larmarange J;
    AIDS Care; 2016; 28 Suppl 3(Suppl 3):39-51. PubMed ID: 27421051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expansion and scale-up of HIV care and treatment services in four countries over ten years.
    Teasdale CA; Abrams EJ; Yuengling KA; Lamb MR; Wang C; Vitale M; Hawken M; Melaku Z; Nuwagaba-Biribonwoha H; El-Sadr WM
    PLoS One; 2020; 15(4):e0231667. PubMed ID: 32298331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid antiretroviral initiation among Thai youth living with HIV in the National AIDS programme in the era of treatment at any CD4 cell count: a national registry database study.
    Teeraananchai S; Kerr SJ; Khananuraksa P; Ruxrungtham K; Puthanakit T
    J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25574. PubMed ID: 32869537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
    Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
    PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of time to antiretroviral treatment initiation and subsequent mortality on treatment in a cohort in rural northern Malawi.
    Brown JP; Ngwira B; Tafatatha T; Crampin AC; French N; Koole O
    AIDS Res Ther; 2016; 13():24. PubMed ID: 27398087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in baseline CD4 cell counts and risk factors for late antiretroviral therapy initiation among HIV-positive patients in Shanghai, a retrospective cross-sectional study.
    Sun J; Liu L; Shen J; Chen P; Lu H
    BMC Infect Dis; 2017 Apr; 17(1):285. PubMed ID: 28420350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An analysis of factors associated with timeliness of antiretroviral therapy initiation among newly diagnosed HIV/AIDS from 2010 to 2014 in China].
    Tang HL; Xu J; Han J; Li J; Mao YR
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Aug; 51(8):711-717. PubMed ID: 28763920
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of Late Testing and Antiretroviral Treatment on Mortality Among People Living With HIV in the Era of Treat-All in Guangdong Province, China, 1992-2018: A Cohort Study.
    Chen Q; Liu J; Fu X; Yang F; Liu Q; Li J; Tan Z; Li J; Lin K; Yan Y; Yang Y; Li Y; Jiang H
    Front Public Health; 2022; 10():851117. PubMed ID: 35875008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the impact of the COVID-19 restrictions on HIV testing services in Malawi: an interrupted time series analysis.
    Afirima B; Iyamu IO; Yesufu ZA; Iwara E; Chilongozi D; Banda L; Zenengeya E; Mablekisi C; Matatiyo B; Kuye J; Michael O; Gonani A; Ruberintwari M; Madidi N; Oladele E; Akolo C
    Afr J AIDS Res; 2023 Jul; 22(2):92-101. PubMed ID: 37395508
    [No Abstract]   [Full Text] [Related]  

  • 35. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
    Molina JM; Grund B; Gordin F; Williams I; Schechter M; Losso M; Law M; Ekong E; Mwelase N; Skoutelis A; Wiselka MJ; Vandekerckhove L; Benfield T; Munroe D; Lundgren JD; Neaton JD;
    Lancet HIV; 2018 Apr; 5(4):e172-e180. PubMed ID: 29352723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale-up in Malawi.
    Tweya H; Feldacker C; Mpunga J; Kanyerere H; Heller T; Ganesh P; Nkosi D; Kalulu M; Sinkala G; Satumba T; Phiri S
    J Int AIDS Soc; 2019 Apr; 22(4):e25240. PubMed ID: 31038836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early mortality after late initiation of antiretroviral therapy in the TREAT Asia HIV Observational Database (TAHOD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Asia-Pacific.
    Rupasinghe D; Kiertiburanakul S; Kamarulzaman A; Zhang F; Kumarasamy N; Chaiwarith R; Merati TP; Do CD; Khusuwan S; Avihingsanon A; Lee MP; Ly PS; Yunihastuti E; Nguyen KV; Ditangco R; Chan YJ; Pujari S; Ng OT; Choi JY; Sim B; Tanuma J; Sangle S; Ross J; Law M
    HIV Med; 2020 Jul; 21(6):397-402. PubMed ID: 31852025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of point-of-care CD4 cell count results on linkage to care and antiretroviral initiation during a home-based HIV testing campaign: a non-blinded, cluster-randomised trial.
    Desai MA; Okal DO; Rose CE; Ndivo R; Oyaro B; Otieno FO; Williams T; Chen RT; Zeh C; Samandari T
    Lancet HIV; 2017 Sep; 4(9):e393-e401. PubMed ID: 28579225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of implementing universal and rapid HIV treatment on initiation of antiretroviral therapy and retention in care in Zambia: a natural experiment using regression discontinuity.
    Mody A; Sikazwe I; Namwase AS; Wa Mwanza M; Savory T; Mwila A; Mulenga L; Herce ME; Mweebo K; Somwe P; Eshun-Wilson I; Sikombe K; Beres LK; Pry J; Holmes CB; Bolton-Moore C; Geng EH
    Lancet HIV; 2021 Dec; 8(12):e755-e765. PubMed ID: 34656208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.